| ￥3000 | |
| Z05210-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | DcR1/TRAILR3, His, Human immobilized on CM5 Chip can bind Human TRAIL, No Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 23.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of DcR1/TRAILR3, His, Human is greater than 95% as determined by SEC-HPLC. »
DcR1/TRAILR3, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
DcR1/TRAILR3, His, Human on CM5 Chip can bind Human TRAIL, No Tag with an affinity constant of 0.57 nM as determined in SPR assay (Biacore T200). »
| Target Background | The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which mediates apoptosis by the extrinsic pathway. Up-regulation of decoy receptors, DcR1 and DcR2, may result in diminished binding of TRAIL to their functional receptors. DcR1 expression occurs in a subset of EC and may contribute to resistance to TRAIL-induced apoptosis. |
| Synonyms | CD263; DCR1; DCR1-TNFR; LIT; TRAIL-R3; TRAILR3; TRID; TNFRSF10C |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
